Scientists Sent Miso to Space to Ferment — and It's Apparently Delicious
Scientists studied miso fermentation on the ISS versus Earth to understand how space conditions affect flavor, texture, and microbial composition.
Space-fermented miso developed a darker color and a 'nutty' and 'roasted' flavor, likely due to higher temperatures and increased pyrazine levels.
The research highlights how microbes adapt in space and raises ethical questions about relocating Earth-based life, while also suggesting new culinary possibilities for long-term space missions.Astronauts aboard the International Space Station (ISS) do a lot of important work to help advance science, including experiments and research to support humanity's potential future as outer space explorers. And that extends to researching how to make food taste better on both long-haul space missions and down here on Earth.
In April, researchers published the findings of their study titled "Food Fermentation in Space" in the open access journal iScience, highlighting the differences in taste between miso fermented on Earth — specifically in Cambridge, Massachusetts and Copenhagen, Denmark — versus miso fermented in the ISS.
If you're unfamiliar with miso, this fermented soybean paste is a powerhouse of flavor. It's a staple in Japanese cooking, and the umami-packed paste can be used for everything from classic miso soup to marinades, salad dressings, and so much more. There are many different varieties of miso and variables that can influence its flavor. But one factor that hadn't been tested until now? Space.
Related: 16 Robust, Complex Miso Recipes, From Pasta to Dessert
For the first stage of this experiment, the scientists made three batches of miso starter and sent it off to the three locations. The misos on board the ISS and in Cambridge were each placed inside an environmental sensing box to carefully monitor variables like temperature, humidity, and radiation levels. The one in Copenhagen was left in a standard container to act as a control group to see if it was the box or space that made changes to the miso.
After a 30-day wait, the miso onboard the ISS was sent back to Earth for analysis against the two already on terra firma, where scientists could measure its texture, color, microbial population, and flavor profiles.
The researchers found that the miso fermented in space had higher levels of certain microbes — microscopic organisms that are crucial to the fermentation process — which they note could be because of the warmer temperatures aboard the ISS.
"While the ISS is often seen as a sterile environment, our research shows that microbes and non-human life have agency in space, raising significant bioethical questions about removing plants and microbes from their home planet and introducing them to extraterrestrial environments," Maggie Coblentz, an industrial design scientist at the Massachusetts Institute of Technology, explains in a statement.
The flavor of the three miso pastes also differed. The researchers found that the space miso exhibited a darker color along with a "nutty" and "roasted" taste, which could be attributed to an increased production of pyrazines — an organic compound that the report says displays "baked, roasted, and nutty flavor characteristics" — in the space miso due to the higher temperatures.
Related: Foods Like Kimchi and Miso May Have Major Mental Health Benefits, New Study Suggests
"By bringing together microbiology, flavor chemistry, sensory science, and larger social and cultural considerations, our study opens up new directions to explore how life changes when it travels to new environments like space," Joshua Evans, a food scientist at the Technical University of Denmark, details.
What does this mean for the future? According to Evans, these learnings "could enhance astronaut well-being and performance, especially on future long-term space missions. More broadly, it could invite new forms of culinary expression, expanding and diversifying culinary and cultural representation in space exploration as the field grows."
Read the original article on Food & Wine
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
3 hours ago
- Business Wire
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ('NIPRO') for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan." Share Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,' said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. 'We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.' About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.


American Military News
4 hours ago
- American Military News
ISS missions with Russia are like working with Nazis, says former US astronaut
This article was originally published by Radio Free Europe/Radio Liberty and is reprinted with permission. A retired US astronaut has told RFE/RL that joint missions with Russia on the International Space Station (ISS) should be scaled back, comparing them to collaboration with Nazi Germany at the height of World War II. 'Cooperating with the Russians on the ISS is like going on an Antarctic expedition with Nazis in 1943,' said Terry Virts, a former commander on the station. 'It's just morally reprehensible,' he added. Since Russia's full-scale invasion of Ukraine in 2022, the ISS is one of the rare areas where cooperation between Russia and the West has continued. Astronauts from both NASA and the European Space Agency (ESA) serve alongside cosmonauts from Russian space agency Roscosmos. Canada and Japan are also involved in what NASA describes 'as one of the most complex international collaborations ever attempted.' 'The station was designed to be interdependent and relies on contributions from across the partnership to function,' NASA says. 'No one partner currently has the capability to function without the other.' Virts does not dispute this but calls for cooperation with Russia to be curtailed. Specifically, he said there are two areas where this would be possible and desirable. Soyuz Versus SpaceX 'We need to stop launching Americans on the Russian Soyuz,' he said, and 'we shouldn't be launching Russian cosmonauts on our rocket while they're actively destroying our friend and ally, Ukraine.' At present, the business of getting people to and from the ISS is shared. Crews and cargo have been ferried back and forth by Soyuz, SpaceX, and recently also Boeing's new Starliner capsule. 'You still need to operate the space station and you can do that…. It's only going to be in service for another few years,' Virts said. 'But I think we should pull back, to say the least.' In a statement provided to RFE/RL, NASA said it flew 'integrated crews' with Roscosmos 'aboard U.S. crew spacecraft and the Soyuz spacecraft to ensure continued safe operations' of the ISS and its crew. For Virts, this is a deeply personal issue. His career has been intimately bound up with the ISS. His maiden voyage as a Space Shuttle pilot in 2010 carried the ISS's final permanent modules, including the largest set of windows ever flown in space. On board the ISS four years later, he witnessed rocket fire in eastern Ukraine as Russian-backed separatists launched an insurgency there. This followed Russian troops seizing Crimea from Ukraine, and Virts says he was shocked by a cosmonaut's response. 'The commander of my Soyuz, Anton Shkaplerov, is from Sevastopol in Crimea. His wife is Ukrainian. And he was like, 'Krym nash, Krym nash,' which means 'Crimea is ours.' He was just so proud that they had taken back Crimea,' Virts said. But later, Virts was more concerned by three other cosmonauts he had flown with — Aleksander Samokutyaev, Maksim Surayev, and Yelena Surova — who all went on to serve as lawmakers in President Vladimir Putin's United Russia party. 'I Felt Betrayed' 'You know, I loved the Russian language and the people and the food. I thought the space station can be this great cooperation instead of conflict. And here they are supporting the most evil, blatantly morally abhorrent war. And that was very painful. I felt betrayed,' he said. Samokutyaev is still serving in Russia's State Duma (parliament) and has been sanctioned by Britain, the European Union, and the United States. The EU sanctions were announced the day after the full-scale invasion, as Samokutyaev had voted to recognize Russian-backed separatist entities in Ukraine as independent states. This was a key move that created the Kremlin's legal pretext for the invasion. The US Treasury said he and other Duma members were sanctioned 'for complicity in Putin's war' due to the vote. Surayev and Surova are no longer in the Duma but have continued to agitate on behalf of Putin and his aggression in Ukraine. For instance, Surayev was a surrogate for Putin in his 2024 election campaign. He can be seen in this video in 2024 in Russian-occupied Donetsk. He was reported by Russian media to have spoken during his visit of the role played by cosmonauts in the 'special military operation,' the Kremlin's preferred term for the full-scale invasion. Surova is now an adviser to the Moscow regional governor. On March 8, Russian media reported she was ceremonially sending off 'aid' to frontline troops in Ukraine, including drones. 'Many committed citizens are helping our defenders by sending vital supplies to the front. Together, we are the only team, a mighty fist, that nobody can defeat,' she reportedly said. A Myth 'Dispelled' None of these former cosmonauts immediately responded to questions from RFE/RL, including how support for Putin and the war in Ukraine aligns with the humanitarian principles of international cooperation in space. Virts said they're not speaking to him, either. 'My Ukrainian friends love me. My Russian friends have stopped talking to me,' he said. There is also controversy surrounding a cosmonaut on the current ISS crew. Alexey Zubritsky was born in Ukraine in 1992 and last month RFE/RL's Current Time reported that he was wanted in the land of his birth for treason. In 2014, Zubritsky was a Ukrainian Air Force pilot stationed in Crimea. When Russian troops arrived, he disobeyed orders to report to a Ukrainian base outside the peninsula, opting instead to stay there and switch sides. The ISS is due to remain in operation until 2030. Shortly after Russian tanks rolled over the Ukrainian border in 2022, Moscow threatened to withdraw from cooperation on the ISS but later said it would remain involved until 2028. 'We have cooperated very well on the space station. We've made a lot of relationships,' said Virts. 'I was on the side of, well, cooperation in space can help things be better on Earth. And man, that myth has been dispelled.'